About
ScreenPoint Medical develops Transpara Breast AI, the industry-leading AI solution purpose-built for the breast imaging continuum. Designed to serve as a reliable 'second pair of eyes,' Transpara assists radiologists in detecting breast cancer earlier and with greater confidence by analyzing both full-field digital mammography (FFDM) and digital breast tomosynthesis (DBT) images. Transpara is backed by the most independent peer-reviewed publications in Breast AI and has participated in three randomized controlled trials (RCTs). In published RCT results, the platform increased cancer detection rates by 29% and reduced radiologist workload by 44%. It excels across diverse variables including patient age, breast density, radiologist experience level, and ethnicity. Key capabilities include AI-driven detection scoring, breast density assessment, and temporal comparison tools that flag changes between studies over time. The solution operates vendor-agnostically, meaning it integrates with mammography equipment and PACS/reading environments from any vendor. It supports single-reading and double-reading workflows without disrupting existing clinical processes. Transpara is FDA cleared and CE marked, and is trusted by leading hospitals, radiology groups, and screening programs across 30+ countries. It is designed for breast imaging practices facing radiologist shortages, rising case volumes, and pressure to deliver personalized, precision medicine. ScreenPoint Medical continuously evolves Transpara with new products and enhanced algorithms to stay at the frontier of AI-driven breast imaging.
Key Features
- AI-Powered Cancer Detection: Analyzes 2D (FFDM) and 3D (DBT) mammograms to flag suspicious findings, acting as a second pair of eyes for radiologists and increasing detection rates by 29% in RCT results.
- Breast Density Assessment: Automatically assesses and reports breast density from mammogram images, supporting clinical decision-making and personalized screening recommendations.
- Temporal Comparison: Compares current mammograms against prior studies to highlight interval changes, enabling earlier identification of developing lesions.
- Workflow Triage & Prioritization: Intelligently triages and prioritizes cases by risk level, allowing radiologists to focus attention on higher-risk exams and achieve a 44% reduction in workload.
- Vendor-Agnostic Integration: Integrates seamlessly with mammography equipment and PACS from any vendor, supporting single-reading and double-reading environments without workflow disruption.
Use Cases
- A hospital radiology department deploys Transpara as a second reader in a single-reading screening program to increase cancer detection rates without adding radiologist headcount.
- A national breast cancer screening program integrates Transpara to triage and prioritize worklists, ensuring high-risk cases are reviewed first and reducing turnaround times.
- A breast imaging practice uses Transpara's temporal comparison feature to detect subtle interval changes between a patient's current and prior mammograms, enabling earlier diagnosis of developing lesions.
- A research institution uses Transpara as part of a prospective randomized controlled trial to measure AI-assisted reading performance versus standard of care across a large patient population.
- A radiology group combating radiologist burnout and workforce shortages adopts Transpara to reduce per-case reading time by 44%, allowing existing staff to safely manage higher screening volumes.
Pros
- Clinically Validated with RCT Evidence: Transpara is backed by the most independent peer-reviewed publications in Breast AI and three randomized controlled trials, giving it a uniquely strong evidence base.
- Significant Workload Reduction: Published RCT data shows a 44% reduction in radiologist workload, directly addressing staffing shortages and burnout in breast imaging programs.
- Broad Regulatory Clearance & Global Reach: FDA cleared and CE marked, with deployments in 30+ countries and performance validated across diverse patient populations, ages, and breast densities.
- Vendor-Agnostic Compatibility: Works with any mammography vendor's equipment, making adoption straightforward for practices regardless of their existing technology stack.
Cons
- Enterprise Pricing, No Self-Serve Option: As a regulated medical device, Transpara requires a formal sales engagement and custom pricing — there is no free trial or public pricing available.
- Specialist Domain Only: The platform is exclusively designed for breast imaging and mammography; it does not extend to other radiology modalities or medical imaging specialties.
- Implementation Requires IT & Workflow Integration: Deploying Transpara in a clinical environment requires PACS/RIS integration and workflow configuration, which may demand technical resources and time from the adopting institution.
Frequently Asked Questions
What types of mammography does Transpara support?
Transpara supports both full-field digital mammography (2D/FFDM) and digital breast tomosynthesis (3D/DBT), and is vendor-agnostic, meaning it works with equipment from any manufacturer.
Is Transpara FDA cleared and CE marked?
Yes. Transpara Breast AI is both FDA cleared for the US market and CE marked for use in Europe, and has been validated across clinical populations in 30+ countries.
What evidence supports Transpara's effectiveness?
Transpara has the most independent peer-reviewed publications of any Breast AI solution and has been evaluated in three randomized controlled trials (RCTs). Published RCT results show a 29% increase in cancer detection and a 44% reduction in radiologist workload.
How does Transpara integrate with existing radiology systems?
Transpara integrates vendor-agnostically with existing PACS and reading workstations. It supports both single-reading and double-reading workflows, fitting into established clinical processes without requiring workflow redesign.
Who is Transpara designed for?
Transpara is designed for breast imaging centers, hospitals, radiology groups, and national screening programs looking to improve cancer detection rates, manage increasing case volumes, and address radiologist staffing challenges.
